Replimune resubmitted data and analyses for its oncolytic virus RP1 in advanced melanoma and the FDA has accepted the filing for a second review, assigning an Apr. 10, 2026 action date. The company also disclosed additional data in the resubmission and said it will work closely with the agency to expedite review. Market reaction was immediate: Replimune shares nearly doubled on the announcement as investors priced in a potential regulatory win.